<?xml version='1.0' encoding='utf-8'?>
<document id="28185946"><sentence text="Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation?"><entity charOffset="10-20" id="DDI-PubMed.28185946.s1.e0" text="tacrolimus" /></sentence><sentence text="Chronic hepatitis C virus (HCV) infection can cause severe liver cirrhosis, for which liver transplantation is the only therapy" /><sentence text=" To prevent organ rejection, transplanted patients are treated with immunosuppressive agents" /><sentence text=" We describe two transplanted patients treated with tacrolimus who were simultaneously treated with direct-acting antivirals (DAAs) for their chronic HCV infection"><entity charOffset="52-62" id="DDI-PubMed.28185946.s4.e0" text="tacrolimus" /></sentence><sentence text=" No pharmacokinetic drug-drug interactions (DDIs) were expected between tacrolimus and the selected DAAs"><entity charOffset="72-82" id="DDI-PubMed.28185946.s5.e0" text="tacrolimus" /></sentence><sentence text=" However, in both patients, tacrolimus plasma concentrations decreased during HCV treatment"><entity charOffset="28-38" id="DDI-PubMed.28185946.s6.e0" text="tacrolimus" /></sentence><sentence text=" We hypothesise that decreased plasma concentrations were not caused by a DDI but were an indirect result of the clearance of the HCV infection" /><sentence text=" During chronic HCV infection, pro-inflammatory cytokines may inhibit cytochrome P450 (CYP) enzymes, which are primarily responsible for tacrolimus metabolism"><entity charOffset="137-147" id="DDI-PubMed.28185946.s8.e0" text="tacrolimus" /></sentence><sentence text=" If this is true, then with clearance of the virus the activity of these enzymes will normalise and tacrolimus metabolism will increase"><entity charOffset="100-110" id="DDI-PubMed.28185946.s9.e0" text="tacrolimus" /></sentence><sentence text=" These changes were clinically relevant because the tacrolimus dosage needed to be adjusted"><entity charOffset="52-62" id="DDI-PubMed.28185946.s10.e0" text="tacrolimus" /></sentence><sentence text=" Therefore, physicians should be aware that CYP substrates with narrow therapeutic ranges might require dose adaption during HCV therapy with DAAs" /><sentence text="" /></document>